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Abstract
Background: Expanded endothelial progenitor cells (eEPC) improve global left ventricular function in experimental
myocardial infarction (MI). Erythropoietin beta (EPO) applied together with eEPC may improve regional myocardial
function even further by anti-apoptotic and cardioprotective effects. Aim of this study was to evaluate
intramyocardial application of eEPCs and EPO as compared to eEPCs or EPO alone in experimental MI.
Methods and Results: In vitro experiments revealed that EPO dosed-dependently decreased eEPC and leukocyte
apoptosis. Moreover, in the presence of EPO mRNA expression in eEPC of proangiogenic and proinflammatory
mediators measured by TaqMan PCR was enhanced. Experimental MI was induced by ligation and reperfusion of
the left anterior descending coronary artery of nude rats (n = 8-9). After myocardial transplantation of eEPC and
EPO CD68+ leukocyte count and vessel density were enhanced in the border zone of the infarct area. Moreover,
apoptosis of transplanted CD31 + TUNEL + eEPC was decreased as compared to transplantation of eEPCs alone.
Regional wall motion of the left ventricle was measured using Magnetic Resonance Imaging. After injection of
eEPC in the presence of EPO regional wall motion significantly improved as compared to injection of eEPCs or EPO
alone.
Conclusion: Intramyocardial transplantation of eEPC in the presence of EPO during experimental MI improves
regional wall motion. This was associated with an increased local inflammation, vasculogenesis and survival of the
transplanted cells. Local application of EPO in addition to cell therapy may prove beneficial in myocardial
remodeling.
Background
Bone marrow derived progenitor cells are mobilized to
the blood in acute myocardial infarction[1-3]. After
recruitment to the ischemic myocardium they contri-
bute to regeneration by neovascularization and release
of paracrine mediators[4-6]. Similarly application of pro-
genitor cells after myocardial infarction has been shown
to improve cardiac function in experimental and clinical
studies [7,8]. Analysis of survival of the applied cells
demonstrated that the vast majority of cells vanished
shortly after transplantation[9]. Therefore additional
treatments to improve the survival of cells may increase
their regenerative capacity and improve myocardial
function after myocardial infarction.
Besides its haematopoietic effects erythropoietin (EPO)
has anti-apoptotic effects especially under ischemic con-
ditions and attenuates oxidative stress[10-14]. Erythro-
poietin receptors are not only expressed on erythroid
precursors, but also on megakaryocytes, vascular smooth
muscle cells, endothelial cells, skeletal myoblasts, neu-
rons, nephrons, and cardiac myocytes. EPO binding to
the EPO receptor leads to a homodimerization, with
subsequent activation of janus kinase 2[15-18]. EPO sig-
naling involves multiple pathways including activation of
STAT 5, activation of proteins with Src homology
2 domains, such as PI3 kinase and activation of ras/
MAP kinases[19]. Proangiogenic properties of EPO and
subsequent cell proliferation and differentiation were
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lial cells with EPO. Furthermore improved wound heal-
ing and angiogenesis was found in mice after application
of EPO [20-22]. Moreover systemic application of EPO
mobilizes progenitor cells from the bone marrow to the
peripheral blood, which was associated with an
improved myocardial function after myocardial infarc-
tion in mice[23,24].
Recent studies have shown that intramyocardial injec-
tion of expanded endothelial progenitor cells (eEPC)
improve global ejection fraction in experimental myo-
cardial infarction (MI) [1].
Aim of this study was to investigate if addition of EPO
to the transplanted eEPC improves regional wall motion
and to investigate the survival of eEPC in the presence
and absence of EPO. As potential mechanisms to alter
regional wall motion the local inflammatory response
and vasculogenesis were analyzed.
Methods
Expansion of EPC (eEPC) and effect of EPO on apoptosis
of mononuclear leukocytes and eEPC in vitro
Mononuclear cells were isolated from human umbilical
cord blood by density gradient centrifugation. CD34+
cells were isolated using immunomagnetic-beads.
CD34+ cord blood cells were cultured in endothelial
medium and expanded to passage 4 and 5 as described
(eEPCs)[6].
Leukocyte suspensions were prepared by dextran sedi-
mentation and hypotonic lysis as described [25]. Apop-
tosis of eEPCs was analyzed in an in vitro apoptosis
assay (Annexin-V-Fluostaining Kit, Roche, Mannheim,
Germany) after H2O2 stimulation for 24 hours and of
leukocytes after serum starvation for 8 hours in
the absence and presence of EPO with the concentra-
tions as indicated (NeoRecormon® Multidose, Roche,
Mannheim). Apoptosis was quantified by flow cytometry
after annexin staining.
Effects of EPO on mRNA expression in vitro
RNA of leukocytes and eEPCs after stimulation with 200
IU/ml EPO for 3 hours and without stimulation was
extracted by Trizol Reagent (Trizol # 15596-026, Invi-
trogen, Germany) according to manufacturer instruc-
tions and cDNA was synthesized as described
previously. Quantitative TaqMan PCR was performed
using Human Inflammatory Cytokines and Receptors
PCR Array and Angiogenesis PCR Array (PAHS-011,
PAHS-024, SABiosciences, Frederick, USA). Assays-on-
Demand containing specific primers and probe for Bax
(Hs00180269_m1) and GAPDH (Hs99999905_m1) were
from Applied Biosystems. Relative RNA expression was
calculated using the ΔΔCt-method by normalization on
GAPDH.
Experimental myocardial infarction
Two models of experimental myocardial infarction were
utilized. To establish the method of measuring regional
wall motion by MRI in large myocardial infarcts we per-
formed a permanent ligation model of the left anterior
descending artery (Lig, n = 8). Since ischemia reperfu-
sion is more relevant for the clinical situation the effects
o fe E P Ci nt h ep r e s e n c ea n da b s e n c eo fE P Oo nr e g i o -
nal wall motion were analyzed using a model of reper-
fused myocardial infarction. Myocardial ischemia was
induced by temporary ligation of the left anterior des-
cending coronary artery for 30 minutes in male athymic
nude rats (CRL:NIH-rnu, Charles River Laboratories,
Sulzfeld, Germany). After reperfusion was initiated by
release of the ligation 1×10
6 eEPC cells in 150 μlP B S
(eEPC n = 9), 1×10
6 eEPC cells in 150 μl PBS containa-
ing 200 U EPO (eEPC + Epo, n = 9), 150 μlP B Sc o n -
taing 200 U EPO (Epo, n = 8) or PBS alone (control,
n = 8) were injected intramyocardial with a 27-gauge
needle as described [1]. To avoid volume disturbances
at the local site of injection and to allow a wider distri-
bution of the transplanted cells, 30 μl injections com-
prising 2 × 10
5 cells per injection site were performed
into 5 sites at distances of about 60° into the borderzone
of the ischemic area. The ischemic zone was identified
by the pale color of the myocardium. Anesthesia was
induced using medetomidin (150 μg/kg), midazolam
(2 mg/kg), and fentanyl (5 μg/kg) and was antagonized
using atipamezol (0.75 mg/kg), flumazenil (200 μg/kg),
and naloxon (120 μg/kg). After 4 weeks cardiac MRI
was performed to assess myocardial function. Subse-
quently, rats were sacrificed by an overdose of pentobar-
bital and hearts were fixed in 4% paraformaldehyde,
embedded in paraffin and sliced into transverse sections.
T h r e eg r o u p sw e r ed e s i g n e da sf o l l o w s :i s c h e m i aa n d
reperfusion (IR; n = 8), permanent ligation (Lig; n = 8)
and sham operation (Sham, n = 6). An additional 5 rats
in each group were sacrificed after 3 days for histologi-
cal analysis. Áll studies were approved by the institu-
tional Animal Care and Use Committee (Bayerisches
Wissenschaftsministerium).
Magnetic resonance imaging
MRI was performed on a clinical 1.5 Tesla Philips
Achieva MR tomograph (Philips Medical System, Best,
The Netherlands) with a small 47 mm flex loop coil. A
dedicated small animal electrocardiographic triggering
system (SA Instruments, USA) was utilized. Cine short
axis images were acquired using a turbo field echo
sequence (TFE) with the following parameters: repeti-
tion time 14 ms, echo time 4.5 ms, flip angle 30°, in-
plane resolution 0.31 × 0.31 mm, image matrix
256 × 256, and slice thickness 2 mm, typically with 5
contiguous slices. The rats were anaesthesized with
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(Dormicum®, Roche; Grenzach-Wyhlen), Medetomidin 2
mg/kg (Dormitor®, Pfizer, Karlsruhe) and Fentanyl 0.005
mg/kg (Ratiopharm, Ulm). The heart rate was between
180 and 210 beats per minute during the scan. Endo-
and epicardial contours were manually traced in end-
diastole and endsystole in contiguous slices covering the
whole left ventricle (LV) followed by calculation of ejec-
tion fraction using MunichHeart/MR [26,27]. For analy-
sis of regional wall motion the left ventricular
circumference was divided into 36 of equally sized sec-
tors and percentage of wall thickening was calculated in
each as the ratio of the difference of end-systolic and
end-diastolic wall thickness to end-systolic wall thick-
ness. For comparison with histology the left ventricular
short axis slice showing the largest circumferential
extent of myocardial infarct scar was aligned with the
corresponding MRI slice (the slice showing lowest wall
motion) using the intersections of the right ventricular
walls and the inter-ventricular septum as landmarks.
Infarct size was determined in histological sections as %
of the LV endocardial circumference as described[28].
Based on histology, three areas of interest were defined:
border zone including four sectors at both ends of the
MI scar, infarcted area including the sectors involved by
MI scar and the remote myocardium covering the rest
of left ventricle. All analyses were done blinded by two
independent investigators.
Immunohistochemistry
Myocardial sections were stained with Masson’sT r i -
chrome staining (MT) for estimation of infarct size.
Immunohistochemical staining was performed incubat-
ing sequential slides with mouse monoclonal antibodies
against rat anti-alpha smooth muscle (clone 1A4, Dako-
Cytomation, Carpinteria, USA) and anti-rat CD68
(Monoclonal mouse Anti-Rat CD68, Serotec, Dusseldorf,
Germany) and staining was achieved using Fast Red
Substrate system (DAKO #K0699, Hamburg, Germany)
and Mayer’s hematoxylin. Infarct size and localization
was determined planimetrically in MT stained slides
using Sigma Scan Pro 5 Image Analysis (Version 5.0,
Aspire Software International, Ashburn, USA). Vessel
density was analyzed after 4 weeks after actin staining
using Axiovision 3.1 (Carl Zeiss Vision GmbH, Jena,
Germany). In 8 randomly selected 20-fold magnified
fields of the infarct border zone the percentage of ves-
sels as fraction of complete field of view area was deter-
mined using S. CORE online image analysis (S.Co
GmbH, Garching, Germany). Early monocytic CD68+
cell infiltration was analyzed after anti-rat CD68 staining
after 3 days. The area of CD68+ cells as percentage of
whole section area was determined planimetrically using
Sigma Scan Pro 5 Image Analysis. Staining for human
CD 31 cells and apoptotic cells was performed after
staining with mouse monoclonal antibody against
human CD 31 (Mouse Anti-Human CD31 monoclonal
antibody, AbD Serotec, Dusseldorf, Germany) and Cy3
anti-mouse IgG (Invitrogen, Karlsruhe, Germany).
Apoptotic cells were visualized with direct Fluorescein
TUNEL labeling (Roche Diagnostics - Applied Science,
Mannheim Germany). Nuclear DNA counterstaining
was performed using VECTASHIELD, Mounting Med-
ium with DAPI (Vector, Laboratories, Burlingame,
USA). Double positive cells for human CD31 and
TUNEL were counted in each section using fluorescence
microscopy. Tissue sections were scored blindly by two
independent investigators (S.K. and E.W.).
Statistical analysis
Values in tables and figures are shown as means ± SEM.
Differences were analyzed by the unpaired Student’st
test or ANOVA as appropriate. P < 0.05 in the two-
tailed test was considered statistically significant.
Results
Effects of EPO on MNC and eEPC apoptosis in vitro
EPO dose-dependently reduced apoptosis in serum-
starved leukocytes (Fig. 1A, B). This inhibition of apop-
tosis was associated with a decreased mRNA expression
of the pro-apoptotic Bax in the presence of EPO (con-
trol: 0.65 + 0.09, EPO: 0.18 + 0.01, n = 4, P = 0.02).
Similary EPO (200 U/l) decreased apoptosis in serum
starved eEPC by 10 + 4% (n = 4) and decreased mRNA
expression of Bax by 15%.
Effects of EPO on inflammatory mediator expression in
eEPCs
After stimulation with EPO, mRNA expression of Plate-
let factor 4 (chemokine (C-X-C motif) ligand 4), a
strong chemoattractant for neutrophils and monocytes
was increased 2.6 fold (p = 0.01) and chemokine recep-
tor 8, involved in lymphocyte recruitment increased 2.7
fold, p = 0.04). Similarly stimulation of eEPC with EPO
resulted in a 2.8 fold increase of secreted phosphopro-
tein 1, a cytokine involved in angiogenesis (Fig. 1C).
Ejection fraction and regional wall thickening after
permanent occlusion or temporary ligation by MRI
To establish the method of regional wall thickening by
MRI we compared the experimental myocardial infarc-
tion after temporary and permanent occlusion. Transi-
ent coronary occlusion resulted in medium size infarcts
while permanent occlusion caused large infarcts as
assessed by immunhistochemistry (I/R: 20 ± 4%, Lig 43
± 4%, p = 0.001). In accordance ejection fraction by
MRI was lower after permanent occlusion than after
transient occlusion (Lig. 36 ± 4%, I/R: 48 ± 1%,
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of the difference of end-systolic and end-diastolic wall
thickness to end-systolic wall thickness, was determined
in the anterolateral segments (Fig. 2). Values in sham
operated rats were 92 ± 7%. Average wall thickening
was reduced in rats with either transient or permanent
ligation in the infarcted area: I/R 11 ± 7%, Lig. 3 ± 3%,
the border zone of the infarction: I/R 14 ± 1%, Lig. 9 ±
2% and the remote myocardium I/R: 48 ± 17%, Lig. 17
± 16% compared to sham operated rats (p < 0.001).
After permanent or transient ligation wall thickening
w a sl e s st h a n2s t a n d a r dd e v i ations of that seen in the
sham operated animals in 98% and 92% of the infarct
segments, in 90% and 92% of the border zone and 93%
and 50% of the remote segments. Regional wall motion
as percentage of systolic wall thickening was determined
in the infarct border zone by matching histological sec-
tions stained with MT and short axis planes of MR ima-
ging (Fig. 2). Regional function of the border zone of
the infarction was significantly reduced in the perma-
nent ligation group by 9 ± 2% compared to rats with
transient ligation (14 ± 1%, p = 0.048). In sham operated
animals we did not see changes in regional wall move-
ment as compared to controla n i m a l s .T h u sr e g i o n a l
wall thickening measured in the infarct border zone that
reflects regional wall motion was improved in the transi-
ent ligation model.
Effects of eEPCs and eEPCs with EPO on the ejection
fraction and regional wall thickening after temporary
ligation by MRI
Regional wall thickening in the infarct border zone was
significantly higher in rats that received eEPCs + EPO
compared to eEPC, EPO alone or controls (Fig. 3B). Yet
this improvement in regional wall motion did not trans-
late into improvement of global systolic left ventricular
function after four weeks (Fig. 3A). Moreover endsysto-
lic and enddiastolic volumes were comparable in all
groups (data not shown). Thus eEPCs in the presence of
EPO as compared to eEPCs or EPO alone induce slight
benefical effects on myocardial function that are
reflected in improvement of regional wall movement.
Figure 1 Pretreatment with EPO dose dependently enhanced survival of leukocytes after serum starvation. (a, b) Stimulation of eEPC
with EPO induced enhanced expression of proangiogenic and proinflammatory factors. (c)
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Infarct size determined in MT-stained histological sec-
tions showed no significant differences after injection of
eEPC: 18 ± 2%, EPO: 21 ± 3% or eEPC + EPO: 22 ± 2
(p = 0.77). Vascularization was determined after four
weeks in sections stained for SMC actin. The number of
vessels was significantly higher in the eEPC + EPO
g r o u pa sc o m p a r e dt oe E P C( 6 . 5±1 %v s .3 . 6±0 . 4 % ;p
= 0.01). In comparison with the EPO and the control
group the eEPC group showed a significantly increased
vascularization in the infarct (Fig 3C).
Recruitment of inflammatory cells to the border zone
of the infarction was evaluated 3 days after myocardial
infarction by staining for mononuclear CD68+ cells.
Quantitative analysis revealed a significantly higher pro-
p o r t i o no fC D 6 8 +c e l l si nt h ee E P C+E P Og r o u p
compared to eEPC, EPO alone or controls, indicating an
increased inflammation (Fig 4A)
After 3 days the number of transplanted cells showing
signs of apoptosis, measured as double positive for
TUNEL and human CD31 staining was significantly
reduced in rats that were treated with eEPCs + EPO as
compared to treatment with eEPCs (7 ± 3% vs. 30 ± 3%;
p = 0.05). (Fig. 4B)
Discussion
The main findings of this study are: (1.) EPO inhibited
apoptosis in leukocytes and eEPCs. (2.) Regional wall
thickening was improved after treatment with eEPCs +
EPO as compared to eEPCs, EPO alone or PBS (con-
trol). This was associated with an increase in inflamma-
tory infiltrate and surviving eEPCs 3 days after
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genesis after 4 weeks.
In a recent study we have shown that eEPC improve
global ejection fraction after intramyocardial transplan-
tation [1]. To evaluate if additional EPO may further
improve myocardial function assessed by MRI these
experiments were performed. Previous studies showed
anti apoptotic effects of EPO on various cell types, such
as endothelial cells and cardiomyocytes[10-12,14]. We
confirmed these anti-apoptotic effects in leukocytes and
eEPCs in vitro. Besides these anti-apoptotic effects, addi-
tional biological functions of EPO on inflammatory or
immune pathways may occur. Previous studies showed
that EPO enhances cellular and humoral components of
the immune system and EPO stimulation of dendritic
cells leads to improved functionality and maturation
[29-32]. We demonstrated an enhanced expression of
lymphocyte and monocyte attractants in eEPCs after sti-
mulation with EPO. This proinflammatory effect was
combined with an enhanced expression of proangiogenic
Platelet factor 4. Taken together EPO stimulation of
eEPC altered the inflammatory expression profile, which
could potentially alter myocardial remodelling by
recruitment of inflammatory cells and enhanced
angiogenesis.
Previous studies mainly examined systemic adminis-
tration of EPO in experimental myocardial infarction
a n do b s e r v e di m p r o v e ds u r v i val, cardiac function and
enhanced progenitor cell mobilization and homing
[10-12,24]. Intramyocardial application of EPO in a
model of permanent ligation of the left anterior des-
cending artery in rats revealed an improved left ventri-
cular function in pressure volume loops, a histological
smaller infarct size and greater capillary density[33-35].
These effects could not been confirmed in the setting of
ischemia and reperfusion in our study, which might be
due to smaller infarctions due to early reperfusion and
different dosages of intra-myocardial injected EPO.
Local application of eEPCs have been shown to
improve myocardial function by enhancing vasculogen-
esis [1]. In the presence of EPO transplantation of
eEPCs improved regional function even further com-
pared to eEPCs alone. Injection of eEPC and EPO was
associated with increased CD68+ inflammatory cell
recruitment and enhanced vessel formation. As a possi-
b l em e c h a n i s mt h ee f f e c to fE P Oo nt h et r a n s p l a n t e d
eEPC, with increased expression of molecules that are
involved in angiogenesis and recruitment of inflamma-
tory cells could be hypothesized. In addition local EPO
may inhibit leukocyte apoptosis. Finally, EPO improves
the survival of the transplanted eEPCs within the border
zone of the myocardial infarction.
Cardiac function was analyzed using MR imaging. This
approach was established using a permanent and
temporary ligation model. Regional wall function mea-
sured in MRI proofed to be a valid and a more sensitive
parameter than global ejection fraction. Alignment of MRI
with histologic infarct areas was reproducible and could
reveal differences that where not detected by measurement
of global ejection fraction. Histologic sections were used
for alignment instead of late enhancement MRI measure-
ments, because of higher accuracy in the identification of
often small and non-transmural infarctions.
The proposed mechanisms of cardiac improvement by
cell transplantation in experimental myocardial infarc-
tion are paracrine effects and enhanced vascularization.
Improvement of regional wall function in the infarct
border zone was observed in rats that received eEPC +
EPO without changing the global ejection fraction or
infarct size. This regional effect was associated with an
increase of paracrine activity of the transplanted cell
presumably due to EPO stimulation and seemed not
sufficient to further increase global systolic function or
infarct size on top of cell transplantation. Previous stu-
dies suggest that regenerative effects of cell therapy are
the more pronounced the bigger the infarction is. The
mainly non-transmural infarctions in this animal model
might be too small to detect any effect concerning ejec-
tion fraction or infarct size and point to the relevance of
more sensitive regional measurements.
In summary transplantation of eEPCs + EPO improves
regional wall thickness by MRI and is associated with
improved eEPC survival, increased inflammatoriy cell
infiltrate and vascularisation. Anti-apoptotic and
immune modulatory effects of EPO may contribute to
this effect. Thus EPO in addition to cell therapy may
prove benefical to improve myocardial remodeling.
Abbreviations
eEPC: expanded endothelial progenitor cells; EPO: erythropoietin; MI:
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